QQ客服 官方微博 反馈留言

浏览/检索结果: 共11条，第1-10条 帮助 限定条件 专题：合肥物质科学研究院    第一署名单位    第一作者单位    通讯作者单位     已选(0)清除 条数/页：5101520253035404550556065707580859095100   排序方式：请选择作者升序作者降序题名升序题名降序发表日期升序发表日期降序提交时间升序提交时间降序 Optical sensing properties of Au nanoparticle/hydrogel composite microbeads using droplet microfluidics 期刊论文 NANOTECHNOLOGY, 2017, 卷号: 28, 期号: 40 作者:  Li, Huilin;  Men, Dandan;  Sun, Yiqiang;  Zhang, Tao;  Hang, Lifeng 收藏  |  浏览/下载：30/0  |  提交时间：2018/08/16 Microfluidic  Au Nanoparticles  Hydrogel  Microbeads  Sensor   Discovery of (R)-1-(3-(4-Amino-3-(3-chloro-4-(pyridin-2-ylmethoxy)phenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one (CHMFL-EGFR-202) as a Novel Irreversible EGFR Mutant Kinase Inhibitor with a Distinct Binding Mode 期刊论文 JOURNAL OF MEDICINAL CHEMISTRY, 2017, 卷号: 60, 期号: 7, 页码: 2944-2962 作者:  Wang, Aoli;  Li, Xixiang;  Wu, Hong;  Zou, Fengming;  Yan, Xiao-E 收藏  |  浏览/下载：34/0  |  提交时间：2018/07/26 Discovery of (R)-1-(3-(4-Amino-3-(3-chloro-4-(pyridin-2-ylmethoxy)phenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one (CHMFL-EGFR-202) as a Novel Irreversible EGFR Mutant Kinase Inhibitor with a Distinct Binding Mode 期刊论文 JOURNAL OF MEDICINAL CHEMISTRY, 2017, 卷号: 60, 期号: 7, 页码: 2944-2962 作者:  Wang, Aoli;  Li, Xixiang;  Wu, Hong;  Zou, Fengming;  Yan, Xiao-E 收藏  |  浏览/下载：41/0  |  提交时间：2018/07/26 Discovery of (R)-1-(3-(4-Amino-3-(3-chloro-4-(pyridin-2-ylmethoxy)phenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one (CHMFL-EGFR-202) as a Novel Irreversible EGFR Mutant Kinase Inhibitor with a Distinct Binding Mode 期刊论文 JOURNAL OF MEDICINAL CHEMISTRY, 2017, 卷号: 60, 期号: 7, 页码: 2944-2962 作者:  Wang, Aoli;  Li, Xixiang;  Wu, Hong;  Zou, Fengming;  Yan, Xiao-E 收藏  |  浏览/下载：34/0  |  提交时间：2018/07/26 Discovery of (R)-1-(3-(4-Amino-3-(3-chloro-4-(pyridin-2-ylmethoxy)phenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one (CHMFL-EGFR-202) as a Novel Irreversible EGFR Mutant Kinase Inhibitor with a Distinct Binding Mode 期刊论文 JOURNAL OF MEDICINAL CHEMISTRY, 2017, 卷号: 60, 期号: 7, 页码: 2944-2962 作者:  Wang, Aoli;  Li, Xixiang;  Wu, Hong;  Zou, Fengming;  Yan, Xiao-E 收藏  |  浏览/下载：30/0  |  提交时间：2018/07/26 Discovery of (R)-1-(3-(4-Amino-3-(3-chloro-4-(pyridin-2-ylmethoxy)phenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one (CHMFL-EGFR-202) as a Novel Irreversible EGFR Mutant Kinase Inhibitor with a Distinct Binding Mode 期刊论文 JOURNAL OF MEDICINAL CHEMISTRY, 2017, 卷号: 60, 期号: 7, 页码: 2944-2962 作者:  Wang, Aoli;  Li, Xixiang;  Wu, Hong;  Zou, Fengming;  Yan, Xiao-E 收藏  |  浏览/下载：36/0  |  提交时间：2018/07/26 Discovery of (R)-1-(3-(4-Amino-3-(3-chloro-4-(pyridin-2-ylmethoxy)phenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one (CHMFL-EGFR-202) as a Novel Irreversible EGFR Mutant Kinase Inhibitor with a Distinct Binding Mode 期刊论文 JOURNAL OF MEDICINAL CHEMISTRY, 2017, 卷号: 60, 期号: 7, 页码: 2944-2962 作者:  Wang, Aoli;  Li, Xixiang;  Wu, Hong;  Zou, Fengming;  Yan, Xiao-E 收藏  |  浏览/下载：26/0  |  提交时间：2018/07/26 Discovery of (R)-1-(3-(4-Amino-3-(3-chloro-4-(pyridin-2-ylmethoxy)phenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one (CHMFL-EGFR-202) as a Novel Irreversible EGFR Mutant Kinase Inhibitor with a Distinct Binding Mode 期刊论文 JOURNAL OF MEDICINAL CHEMISTRY, 2017, 卷号: 60, 期号: 7, 页码: 2944-2962 作者:  Wang, Aoli;  Li, Xixiang;  Wu, Hong;  Zou, Fengming;  Yan, Xiao-E 收藏  |  浏览/下载：16/0  |  提交时间：2018/07/26 Discovery of (R)-1-(3-(4-Amino-3-(3-chloro-4-(pyridin-2-ylmethoxy)phenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one (CHMFL-EGFR-202) as a Novel Irreversible EGFR Mutant Kinase Inhibitor with a Distinct Binding Mode 期刊论文 JOURNAL OF MEDICINAL CHEMISTRY, 2017, 卷号: 60, 期号: 7, 页码: 2944-2962 作者:  Wang, Aoli;  Li, Xixiang;  Wu, Hong;  Zou, Fengming;  Yan, Xiao-E 收藏  |  浏览/下载：7/0  |  提交时间：2018/07/26 Ibrutinib targets mutant-EGFR kinase with a distinct binding conformation 期刊论文 ONCOTARGET, 2016, 卷号: 7, 期号: 43, 页码: 69760-69769 作者:  Wang, Aoli;  Yan, Xiao-E;  Wu, Hong;  Wang, Wenchao;  Hu, Chen 收藏  |  浏览/下载：79/0  |  提交时间：2017/11/21 Ibrutinib  Egfr Kinase  Dfg-in/c-helix-out  Inactive Conformation  Nsclc